Rates and trends in stage‐specific prostate cancer incidence by age and race/ethnicity, 2000–2017. Issue 14 (28th July 2021)

• Record Type: Journal Article
• Authors: Cao, Yubo; Zhang, Wei; Li, Yue; Fu, Jia; Li, Hongyuan; Li, Xiulin; Gao, Xue; Zhang, Kaiyu; Liu, Sa
• Is Part Of: Prostate. Volume 81:Issue 14(2021)
• Page Start: 1071
• Page End: 1077
• Publication Date: 2021-07-28
• Subjects: prostate cancer incidence -- PSA screening -- SEER program -- USPSTF guideline; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.24204
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Background: The 2008 and 2012 United States Preventive Services Task Force (USPSTF) recommendations against prostate‐specific antigen (PSA) screening have led to changes in the incidence pattern of prostate cancer. We sought to examine rates and trends in stage‐specific prostate cancer incidence by age and race/ethnicity using the most recent data obtained from Surveillance, Epidemiology, and End Results (SEER) program. Methods: SEER*Stat version 8.3.6 was used to analyze annual prostate cancer incidence rates between 2000 and 2017 according to the SEER summary stage, age group, and race/ethnicity group. Incidence rates per 100, 000 men were calculated and age‐adjusted to 2000 US standard population. Annual percentage change (APC) was performed to identify the trend in prostate cancer incidence. Results: Between 2008 and 2012, trends in incidence of overall and localized prostate cancer significantly declined in comparison with between 2000 and 2007 (APC, −5.4 and −6.0, respectively). However, there was an increase in the incidence rate of both overall and localized prostate cancer from 2014 to 2017 (43.3–46 and 34–34.9 per 100, 000 men, respectively). The incidence of regional prostate cancer significantly increased between 2013 and 2017 (5.9–6.8 per 100, 000 men; APC, 4.3). Distant disease incidence increased continually between 2008 and 2012 (2.9–3.3 per 100, 000 men; APC, 2.3) and between 2013 and 2017 (3.4–4.3 per 100, 000 men; APC, 6.0). In addition, these increases in incidence occurred in men of all stratified age and race/ethnicity groups, except for men aged <50 years and American Indian/Alaska Native men. Conclusion: This study demonstrates that the longer‐term effects of USPSTF recommendations against PSA screening may have resulted in a reversal of downtrend in prostate cancer incidence, as incidence rates of overall and localized prostate cancer gradually increased from 2014 to 2017. Meanwhile, the trend in stage migration toward advanced disease increased incrementally.